Literature DB >> 27023678

Thiobarbituric Acid-Reactive Substances: Markers of an Acute Episode and a Late Stage of Bipolar Disorder.

Marcin Siwek1, Magdalena Sowa-Kucma, Krzysztof Styczen, Paulina Misztak, Bernadeta Szewczyk, Roman Topor-Madry, Gabriel Nowak, Dominika Dudek, Janusz K Rybakowski.   

Abstract

BACKGROUND: Lowered antioxidant defense systems and increased oxidative stress are implicated in bipolar disorders (BD). Early and late stages of BD may present different biological features (including the level of oxidative stress) and may therefore require different treatment strategies. The aim of this study was to analyze serum levels of lipid peroxidation [measured as thiobarbituric acid-reactive substances (TBARS), a derivative of malondialdehyde] in BD patients at various stages and phases of the illness and compare their TBARS levels with those of healthy controls.
METHOD: A total of 129 patients (58 in the depressive episode, 23 in the manic episode and 48 in remission) diagnosed with type I (n = 69) or type II (n = 60) BD and 50 healthy volunteers (control group) were enrolled in the study. The level of lipid peroxidation was measured in blood serum using a TBARS assay kit.
RESULTS: TBARS levels in the acute episode of mania/hypomania and depression (but not in remission) were significantly higher than in healthy controls. With regard to the BD stage, both early- and late-stage BD TBARS levels were significantly increased in patients in the depressive episode. In late-stage BD, the TBARS level in patients in remission remained elevated compared with controls. A multiple regression model confirmed the association between the TBARS level and BD stage or acute BD.
CONCLUSION: Our findings indicate that TBARS levels reflect the oxidative stress state which increases both in the acute phase of BD (mania/hypomania and depression) and with BD progression (stage).
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27023678     DOI: 10.1159/000444491

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  8 in total

Review 1.  Targeting Mitochondrial Dysfunction for Bipolar Disorder.

Authors:  Maya Kuperberg; Sophie L A Greenebaum; Andrew A Nierenberg
Journal:  Curr Top Behav Neurosci       Date:  2021

2.  Resveratrol protects the brain against oxidative damage in a dopaminergic animal model of mania.

Authors:  Samira Menegas; Camila L Ferreira; José Henrique Cararo; Fernanda F Gava; Gustavo C Dal-Pont; Maria L Gomes; Jotele F Agostini; Patrícia Fernanda Schuck; Giselli Scaini; Monica L Andersen; João Quevedo; Samira S Valvassori
Journal:  Metab Brain Dis       Date:  2019-03-27       Impact factor: 3.584

Review 3.  Na⁺, K⁺-ATPase Signaling and Bipolar Disorder.

Authors:  David Lichtstein; Asher Ilani; Haim Rosen; Noa Horesh; Shiv Vardan Singh; Nahum Buzaglo; Anastasia Hodes
Journal:  Int J Mol Sci       Date:  2018-08-07       Impact factor: 5.923

Review 4.  Concepts of Neuroinflammation and Their Relationship With Impaired Mitochondrial Functions in Bipolar Disorder.

Authors:  Luiz Arthur Rangel Cyrino; Daniela Delwing-de Lima; Oliver Matheus Ullmann; Thayná Patachini Maia
Journal:  Front Behav Neurosci       Date:  2021-02-26       Impact factor: 3.558

Review 5.  Therapeutic Interventions to Mitigate Mitochondrial Dysfunction and Oxidative Stress-Induced Damage in Patients with Bipolar Disorder.

Authors:  Sahithi Madireddy; Samskruthi Madireddy
Journal:  Int J Mol Sci       Date:  2022-02-06       Impact factor: 5.923

6.  Neuroinflammation and neuroprogression produced by oxidative stress in euthymic bipolar patients with different onset disease times.

Authors:  Daniela Delwing-de Lima; Luiz Arthur Rangel Cyrino; Gabriela Kozuchovski Ferreira; Débora Delwing Dal Magro; Claudia Regina Calegari; Heloisi Cabral; Natalia Cavichioli; Silvia Aparecida Ramos; Oliver Matheus Ullmann; Yasmin Mayer; Luana Carla Pscheidt; Maria Augusta Schramm; Maria Cecília Tomasi; Felipe Luis Schmoller Stammerjohann; Larissa Delmonego; Maria Helena Packer; Heloiza Fiamoncini
Journal:  Sci Rep       Date:  2022-10-06       Impact factor: 4.996

7.  The serum zinc concentration as a potential biological marker in patients with major depressive disorder.

Authors:  Krzysztof Styczeń; Magdalena Sowa-Kućma; Marcin Siwek; Dominika Dudek; Witold Reczyński; Bernadeta Szewczyk; Paulina Misztak; Roman Topór-Mądry; Włodzimierz Opoka; Gabriel Nowak
Journal:  Metab Brain Dis       Date:  2016-08-08       Impact factor: 3.584

8.  The Staging of Major Mood Disorders: Clinical and Neurobiological Correlates.

Authors:  Ather Muneer; Rana Mazommil
Journal:  Psychiatry Investig       Date:  2018-08-20       Impact factor: 2.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.